Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Post by Fullblaston Apr 13, 2016 6:42pm
152 Views
Post# 24764031

Valeant is on track for its 10-K

Valeant is on track for its 10-K
Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters

Company is on Schedule to File its 10-K on or before April 29, 2016, as Previously Disclosed

LAVAL, Quebec, April 13, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today provided an update on regulatory matters.

As previously disclosed, the Autorit des marchs financiers (the company's principal securities regulator in Canada) issued a customary management cease trade order ("MCTO") on March 31, 2016 relating to the trading in securities of the company by the company's CEO and CFO and each other member of the company's board of directors. Keeping with common practice, an MCTO relating to a director of the company who is resident in Ontario was issued by the Ontario Securities Commission on that same date. The MCTOs do not affect the ability of other shareholders to trade in the securities of the company. 

The MCTO was issued in response to an application made by the company in connection with the company's delay in filing its audited annual financial statements for the year ended December 31, 2015 (together with the required associated filings, the "Canadian Required Filings") with Canadian securities regulators by the March 30, 2016 filing deadline.    

In connection with the issuance of the MCTOs, and in accordance with its obligation to provide bi-weekly updates under the alternative information guidelines set out in National Policy 12-203 Cease Trade Orders for Continuous Disclosure Defaults, the company confirms that it has fulfilled its stated intentions regarding compliance with such alternative information guidelines and that, except as previously disclosed, there have been no material changes to the information relating to the company's delay in making the Canadian Required Filings or its other required filings under applicable Canadian securities laws or otherwise concerning the affairs of the company.  The Company is working diligently to make the Canadian Required Filings on or before April 29, 2016.


<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse